Skip to main content
SpringerLink
Log in
Book cover

Antiphospholipid Syndrome pp 189–199Cite as

Disease and Risk Measurement Criteria in Antiphospholipid Syndrome

  • Chapter
  • First Online:

  • 1220 Accesses

Abstract

Evaluating risk profile in patients with antiphospholipid antibodies (aPL) is an unmet need. Two recently proposed risk prediction scoring systems, aPL score and global APS score (GAPSS), are useful risk quantification tools for both thrombosis and pregnancy morbidity; they change the concept of aPL from that of “diagnostic antibodies” to “risk factors” for clinical events. Because some manifestations of aPL carry a dire prognosis, and because permanent damage may occur, a damage index for APS (DIAPS) has been developed and validated. The consequences of permanent damage due to thrombosis in APS patients decrease the health-related quality of life (HRQoL).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

    Article  CAS  PubMed  Google Scholar 

  2. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64:504–12.

    Article  CAS  PubMed  Google Scholar 

  3. Sciascia S, Bertolaccini ML. Thrombotic risk assessment in APS: the Global APS Score (GAPSS). Lupus. 2014;23:1286–7.

    Article  CAS  PubMed  Google Scholar 

  4. Sciascia S, Sanna G, Murru V, et al. The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxford). 2015;54:134–8.

    Article  Google Scholar 

  5. Oku K, Amengual O, Bohgaki T, Horita T, Yasuda S, Atsumi T. An independent validation of the global anti-phospholipid syndrome score in a Japanese cohort of patients with autoimmune diseases. Lupus. 2015;24:774–5.

    Article  CAS  PubMed  Google Scholar 

  6. Zuily S, de Laat B, Mohamed S, et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology. 2015;54:2071–5.

    Article  PubMed  Google Scholar 

  7. Amigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus. 2015;24:927–34.

    Article  PubMed  Google Scholar 

  8. Zuily S, Rat A-C, Regnault V, et al. Impairment of quality of life in patients with antiphospholipid syndrome. Lupus. 2015;24:1161–8.

    Article  CAS  PubMed  Google Scholar 

  9. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am J Med. 1996;100:530–6.

    Article  CAS  PubMed  Google Scholar 

  10. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93:1147–52.

    CAS  PubMed  Google Scholar 

  11. Gresele P, Migliacci R, Vedovati MC, et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res. 2009;123:444–51.

    Article  CAS  PubMed  Google Scholar 

  12. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7:330–9.

    Article  CAS  PubMed  Google Scholar 

  13. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. NEJM. 2013;368:1033–44.

    Article  CAS  PubMed  Google Scholar 

  14. Oku K, Amengual O, Atsumi T. Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. Eur J Clin Investig. 2012;42:1126–35.

    Article  CAS  Google Scholar 

  15. Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol. 2004;16:1633–41.

    Article  CAS  PubMed  Google Scholar 

  16. Oku K, Amengual O, Zigon P, Horita T, Yasuda S, Atsumi T. Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. Rheumatology (Oxford). 2013;52:1775–84.

    Article  CAS  Google Scholar 

  17. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z, et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost JTH. 2007;5:1828–34.

    Article  CAS  PubMed  Google Scholar 

  18. Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res. 2004;114:467–76.

    Article  CAS  PubMed  Google Scholar 

  19. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74:1185–90.

    CAS  PubMed  Google Scholar 

  20. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR. Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol. 1996;35:1239–43.

    Article  CAS  PubMed  Google Scholar 

  21. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000;43:1982–93.

    Article  CAS  PubMed  Google Scholar 

  22. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol. 1987;68:215–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Oku K, Amengual O, Atsumi T. Antiphospholipid scoring: significance in diagnosis and prognosis. Lupus. 2014;23:1269–72.

    Article  CAS  PubMed  Google Scholar 

  24. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the global anti-phospholipid syndrome score. Rheumatology (Oxford). 2013;52:1397–403.

    Article  Google Scholar 

  25. Bertolaccini ML, Amengual O, Atsumi T, et al. ‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011;20:191–205.

    Article  CAS  PubMed  Google Scholar 

  26. Sciascia S, Cuadrado MJ, Sanna G, et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. Arthritis Care Res (Hoboken). 2014;66:1915–20.

    Article  Google Scholar 

  27. Erkan D, Yazici Y, Sobel R, Lockshin MD. Functional outcome after 10 years. J Rheumatol. 2000;27:2817–2.

    CAS  PubMed  Google Scholar 

  28. Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a 10 years follow-up of 52 patients. Lupus. 1998;7:3–6.

    Article  CAS  PubMed  Google Scholar 

  29. Cervera R, Khamashta MA, Shoenfeld Y, et al. Euro-phospholipid project group morbidity and mortality in the antiphospholipid syndrome during 5 year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68:1428–32.

    Article  CAS  PubMed  Google Scholar 

  30. Mathew S, Cesario S, Symes L. Explaining “unexplained” perinatal loss. Experiences of women with antiphospholipid syndrome. J Perinat Neonat Nurs. 2008;22:293–301.

    Article  Google Scholar 

  31. Grika EP, Ziakas PD, Zintzaras E, Moutsopoulos HM, Vlachoyiannopoulos PG. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol. 2012;39:516–23.

    Article  PubMed  Google Scholar 

  32. Barbhaiya M, Erkan D, Rodriguez-Alamaraz E, Ramón G, Vega J, Lockshin MD. Utility of the Systemic Lupus International Collaborating Clinics (SLICC) American College of Rheumatology (ACR) Damage Index for antiphospholipid antibody (aPL) positive patients. Arthritis Rheum. 2011;63 Suppl:S3.

    Google Scholar 

  33. Feinstein AR. Clinimetrics. London: Yale University Press; 1987.

    Google Scholar 

  34. Ugolini Lopes MR, Aguila LA, Tonon RC et al. SLICC and DIAPS. Potential indices for damage assessment in primary antiphospholipid syndrome (PAPS). Presented at APLA & LACA 2013, 14th International Congress on Antiphospholipid Antibodies. 18–21 Sept 2013, Rio de Janeiro.

    Google Scholar 

  35. Abreu MM, Danowski A, Wahl DG, et al. The relevance of non criteria clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14:401–4.

    Article  PubMed  Google Scholar 

  36. Amezcua-Guerra LM. Improving definitions for an index of cumulative organ damage in patients with the antiphospholipid syndrome (DIAPS). Letter to the Editor. Lupus. 2016;25:671–2.

    Article  CAS  PubMed  Google Scholar 

  37. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-rated health question. A meta-analysis. J Gen Intern Med. 2006;21:267–75.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med. 2002;162:1144–8.

    Article  PubMed  Google Scholar 

  39. Khanna S, Pal H, Pandey RM, Handa R. The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatol Oxf Engl. 2004;43:1536–40.

    Article  CAS  Google Scholar 

  40. Jolly M, Utset TO. Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? Lupus. 2004;13:924–6.

    Article  CAS  PubMed  Google Scholar 

  41. Gladman DD, Urowitz MB, Ong A, Gough J, MacKinnon A. Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol. 1996;14:305–8.

    CAS  PubMed  Google Scholar 

  42. Ware J, Kosinski M, Keller D. SF-36 physical and mental health summary scales: a User’s manual. Boston: The Health Institute, New England Medical Center; 1994.

    Google Scholar 

  43. Leplège A, Ecosse E, Pouchot J. Data from general population. In: The MOS SF-36 questionnaire. User manual and interpretation guide scores. ESTEM; Paris, France 2001. p. 67–77.

    Google Scholar 

  44. Ware J, Snow K, Kosinski M. SF-36 health survey manual and interpretation guide. Boston: The Health Institute NEMC; 1993.

    Google Scholar 

  45. EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy Amst Neth. 1990;16:199–208.

    Article  Google Scholar 

  46. Oliveira de Andrade DC, Borba EF, Bonfá E, Freire de Carvalho J, José da Rocha A, Carlos Maia A. Quantifying subclinical central nervous lesions in primary antiphospholipid syndrome: the role of magnetization transfer imaging. J Magn Reson Imaging JMRI. 2008;27:483–8.

    Article  PubMed  Google Scholar 

  47. Wang C, Mayo NE, Fortin PR. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol. 2001;28:525–32.

    CAS  PubMed  Google Scholar 

  48. Costa SP, Lage LV, da Mota LMH, de Carvalho JF. Fibromyalgia in primary antiphospholipid (Hughes) syndrome. Lupus. 2011;20:1182–6.

    Article  CAS  PubMed  Google Scholar 

  49. Georgopoulou S, Efraimidou S, MacLennan SJ, Ibrahim F, Cox T. Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36. Lupus. 2015;24:174–9.

    Article  CAS  PubMed  Google Scholar 

  50. Balitsky AK, Peeva V, Su J, et al. Thrombovascular events affect quality of life in patients with systemic lupus erythematosus. J Rheumatol. 2011;38:1017–9.

    Article  PubMed  Google Scholar 

  51. Brown N, Melville M, Gray D, et al. Quality of life four years after acute myocardial infarction: short form 36 scores compared with a normal population. Heart Br Card Soc. 1999;81:352–8.

    CAS  Google Scholar 

  52. van Korlaar IM, Vossen CY, Rosendaal FR, et al. The impact of venous thrombosis on quality of life. Thromb Res. 2004;114:11–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ABC Medical Center, Department of Rheumatology, Mexico City, Mexico

    Mary-Carmen Amigo

  2. Academic Department of Vascular surgery, Cardiovascular Division, King’s College London, St Thomas’ Hospital, London, UK

    Maria Laura Bertolaccini

  3. Nancy University Hospital, Department of Cardio-Vascular Medicine, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Insitut Lorrain du Coeur et des Vaisseaux, Vandoeuvre-lès-Nancy Cedex, France

    Denis Wahl

  4. Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan

    Kenji Oku

  5. Center of Research of Immunopathology and Rare Diseases, Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, San Giovanni Hospital, University of Torino, Torino, Italy

    Savino Sciascia

  6. Investigadora Titular, Hospital General Regional No. 1 IMSS, Unidad de Investigación en Epidemiología Clínica, Ciudad de México, Mexico

    María Victoria Goycochea Robles

  7. Nancy University Hospital, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Vandoeuvre-lès-Nancy Cedex, France

    Stéphane Zuily

  8. Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan

    Olga Amengual

  9. San Giovanni Hospital, Center of Research of Immunopathology and Rare Diseases; and SCDU Nephrology and Dialysis, Torino, Italy

    Dario Roccatello

  10. Department of Rheumatology, Keio University School of Medicine, Shinjuku, Tokyo, Japan

    Kotaro Otomo

  11. Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan

    Tatsuya Atsumi

Authors
  1. Mary-Carmen Amigo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenji Oku
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Savino Sciascia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. María Victoria Goycochea Robles
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stéphane Zuily
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Olga Amengual
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dario Roccatello
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kotaro Otomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tatsuya Atsumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Maria Laura Bertolaccini
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Denis Wahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary-Carmen Amigo .

Editor information

Editors and Affiliations

  1. The Barbara Volcker Center for Women and Rheumatic Diseases, Associate Attending Physician, Hospital for Special Surgery, Associate Professor of Medicine, Weill Cornell Medicine, New York, New York, USA

    Doruk Erkan

  2. The Barbara Volcker Center for Women and Rheumatic Diseases, Attending Physician, Hospital for Special Surgery, Professor of Medicine and Obstetrics-Gynecology, Weill Cornell Medicine, New York, New York, USA

    Michael D. Lockshin

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Amigo, MC. et al. (2017). Disease and Risk Measurement Criteria in Antiphospholipid Syndrome. In: Erkan, D., Lockshin, M. (eds) Antiphospholipid Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-319-55442-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-55442-6_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-55440-2

  • Online ISBN: 978-3-319-55442-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation